PART I BUSINESS COMPANY OVERVIEW We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neuro...
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001689548-26-000029 | EDGAR | 102K words |
| 2025-02-28 | 2024-12-31 | 0001689548-25-000040 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0001689548-24-000034 | EDGAR | — |
| 2023-02-07 | 2022-12-31 | 0001689548-23-000044 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001689548-22-000014 | EDGAR | — |
| 2021-03-17 | 2020-12-31 | 0001689548-21-000016 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001689548-25-000111 | EDGAR | 19K words |
| 2025-08-04 | 2025-06-30 | 0001689548-25-000092 | EDGAR | — |
| 2025-05-02 | 2025-03-31 | 0001689548-25-000058 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001689548-24-000101 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001689548-24-000088 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0001689548-24-000060 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001689548-23-000159 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001689548-23-000128 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001689548-23-000086 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001689548-22-000125 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001689548-22-000111 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0001689548-22-000038 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001689548-26-000031 | EDGAR | 1K words |
| 2026-02-19 | 0001689548-26-000028 | EDGAR | — |
| 2026-01-08 | 0001689548-26-000005 | EDGAR | — |
| 2026-01-07 | 0001104659-26-001825 | EDGAR | — |
| 2026-01-06 | 0001689548-26-000002 | EDGAR | — |
| 2025-12-29 | 0001689548-25-000118 | EDGAR | — |
| 2025-12-11 | 0001689548-25-000116 | EDGAR | — |
| 2025-12-08 | 0001689548-25-000114 | EDGAR | — |
| 2025-11-05 | 0001689548-25-000110 | EDGAR | — |
| 2025-10-21 | 0001689548-25-000103 | EDGAR | — |
126 total filings indexed. 98 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001689548 |
| Ticker | PRAX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.praxismedicines.com |
| Listed | 2020-10-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report